ACADIA Pharmaceuticals
Founded Year
1993Stage
PIPE | IPOTotal Raised
$47.7MMarket Cap
3.13BStock Price
19.09About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals, formerly Recptor Technologies, is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company has five drug programs in clinical and preclinical development. ACADIA's three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease currently in Phase II clinical trials, and ACP-104 and ACP-103, both for the treatment of schizophrenia. The company has two preclinical programs for the development of drug candidates for neuropathic pain and glaucoma in collaboration with Allergan.
Missing: ACADIA Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: ACADIA Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
ACADIA Pharmaceuticals Patents
ACADIA Pharmaceuticals has filed 79 patents.
The 3 most popular patent topics include:
- Piperidines
- Piperazines
- Fluoroarenes
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
12/14/2017 | 10/11/2022 | Piperazines, Fluoroarenes, Atypical antipsychotics, Psychiatric diagnosis, Piperidines | Grant |
Application Date | 12/14/2017 |
|---|---|
Grant Date | 10/11/2022 |
Title | |
Related Topics | Piperazines, Fluoroarenes, Atypical antipsychotics, Psychiatric diagnosis, Piperidines |
Status | Grant |
Latest ACADIA Pharmaceuticals News
Jan 11, 2023
Analysis indicates that Acadia Pharmaceuticals Inc’s pimavanserin is the only FDA-approved medication for the treatment of delusions and hallucinations associated with PDP.
ACADIA Pharmaceuticals Frequently Asked Questions (FAQ)
When was ACADIA Pharmaceuticals founded?
ACADIA Pharmaceuticals was founded in 1993.
Where is ACADIA Pharmaceuticals's headquarters?
ACADIA Pharmaceuticals's headquarters is located at 3911 Sorrento Valley Boulevard, San Diego.
What is ACADIA Pharmaceuticals's latest funding round?
ACADIA Pharmaceuticals's latest funding round is PIPE.
How much did ACADIA Pharmaceuticals raise?
ACADIA Pharmaceuticals raised a total of $47.7M.
Who are the investors of ACADIA Pharmaceuticals?
Investors of ACADIA Pharmaceuticals include AAC Capital Partners, Oxford Bioscience Partners, T. Rowe Price, BVF Partners, Finsbury Worldwide Pharmaceutical Trust plc and 11 more.
Who are ACADIA Pharmaceuticals's competitors?
Competitors of ACADIA Pharmaceuticals include Alexza Pharmaceuticals and 4 more.
Compare ACADIA Pharmaceuticals to Competitors
Relevare Pharmaceuticals, formerly CNSBio, is a specialty pharmaceutical company focused on the development of novel therapies to treat chronic and acute pain. Relevare Pharmaceuticals exciting clinical-stage pipeline is comprised of programs that combine or reposition drugs known to be active at CNS targets that modulate pain perception and transmission, and for which there is strong safety evidence in humans. In April 2010, CNSBio rebranded to Relevare Pharmaceuticals.
Can-Fite is an Israeli science-based biopharmaceutical company with the mission to develop treatments for autoimmune diseases and cancer. The company's drugs which piggyback on a natural mechanism, are small molecules, orally administered, induce specific activity towards their target pathological cells and demonstrated an excellent safety profile in human clinical studies.
APT Therapeutics develops acute-use drugs for controlling clot formation in stroke, pulmonary embolism, myocardial infarction, deep vein thrombosis, and transplantation.
Uh-Oh Labs develops diagnostic tests through their Loop-de-Loop platform which enables simplicity, speed, and lower costs while providing accurate, lab-grade results. The company was founded in 2018 and is based in Santa Clara, CA.
Baebies developed a nimble bioassay automation platform to rapidly perform multiplex enzymatic assays and other tests. The company licensed its core technology, digital microfluidics, from Illumina. In addition to a technology license in newborn screening that does not include sequencing, Baebies also received equipment, contracts, and other consideration in exchange for a share of ownership in the new company. The company was founded in 2013 and is based in Durham, North Carolina.
Urigen specializes in the design and commercialization of innovative products for patients with urological ailments. The company develops products for amelioration of Painful Bladder Syndrome (PBS), Urethritis, Nocturia and Over Active Bladder (OAB).
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.